Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HARMONi-7: Ivonescimab vs pembrolizumab in first-line metastatic NSCLC with high PD-L1
jRCT2031250093Phase 3Recruiting
- Sponsor
- Summit Therapeutics
- Start
- Nov 2025
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial of ivonescimab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Summit Therapeutics. Primary endpoints: Overall survival and Progression-free survival by IRRC. Started Nov 2025; status: recruiting.
02
Drugs
ivonescimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2031250093.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250093.